Abstract:A comprehensive summary of recent advances in SARS‐CoV‐2 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives), including the inhibitory activities, inhibitory mechanisms, and key structural features, provides new insights for designing and developing more efficacious 3CLpro inhibitors as broad‐spectrum anti‐coronavirus agents. The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CLpros play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus‐caused infectious diseases, including COVID‐19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) main protease Mpro (also known as 3CLpro), as well as recent advances in discovering and developing SARS‐CoV‐2 3CLpro inhibitors. To better understand the characteristics of SARS‐CoV‐2 3CLpro inhibitors, the inhibition activities, inhibitory mechanisms, and key structural features of various 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives) are summarized comprehensively. Meanwhile, the challenges in this field are highlighted, while future directions for designing and developing efficacious 3CLpro inhibitors as novel anti‐coronavirus therapies are also proposed. Collectively, all information and knowledge presented here are very helpful for understanding the structural features and inhibitory mechanisms of SARS‐CoV‐2 3CLpro inhibitors, which offers new insights or inspiration to medicinal chemists for designing and developing more efficacious 3CLpro inhibitors as novel anti‐coronavirus agents.

Activation and Maturation of Sars-Cov Main Protease

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Insight into the activity of SARS main protease: Molecular dynamics study of dimeric and monomeric form of enzyme.

Maturation Mechanism of Severe Acute Respiratory Syndrome (SARS) Coronavirus 3C-Like Proteinase.

Progress of SARS‐CoV‐2 Main Protease Peptide‐like Inhibitors

Progress of SARS-CoV-2 Main protease peptide-like inhibitors

Production of Authentic SARS-CoV M(pro) with Enhanced Activity: Application As a Novel Tag-Cleavage Endopeptidase for Protein Overproduction.

1 H, 13 C and 15 N resonance assignments of SARS-CoV main protease N-terminal domain

Structural biology of SARS-CoV-1/SARS-CoV-2 main protease

Three-dimensional domain swapping as a mechanism to lock the active conformation in a super-active octamer of SARS-CoV main protease

A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link Between Three Residues C22, C44, and K61 is Frequently Observed in the SARS-CoV-2 Main Protease.

Structure and Dynamics of SARS Coronavirus Main Proteinase (Mpro).

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

C-Terminal Domain of Sars-Cov Main Protease Can Form A 3d Domain-Swapped Dimer

Without Its N-Finger, the Main Protease of Severe Acute Respiratory Syndrome Coronavirus Can Form a Novel Dimer Through Its C-Terminal Domain

The Crystal Structures of Severe Acute Respiratory Syndrome Virus Main Protease and Its Complex with an Inhibitor

Ph-Dependent Conformational Flexibility of the SARS-CoV Main Proteinase (mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses

1H, 13C, and 15N Resonance Assignments of the N-terminal Domain of the SARS CoV Nucleocapsid Protein.

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Crystal structures of main protease (M pro ) mutants of SARS-CoV-2 variants bound to PF-07304814